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lung cancer risk that is independent of behavior, and therefore, not in-
ﬂuenced by quitting.
The authors addressed this question using a meta-analytic approach
involving 15 studies that examinedmore than 12,000 smokers (Chen et
al., 2016). The study found that therewere no differences in the beneﬁts
of quitting based on CHRNA5 allelic status. Consistent withmany previ-Smokers are very often told that quitting smoking will produce
substantial health beneﬁts, even after decades of smoking. This advice
is based upon an abundance of evidence that would seem to establish
these facts with certainty (Fagerstrom, 2002). In this issue of
EBioMedicine, the paper by Chen et al. (2016) addresses a very impor-
tant question: Does quitting smoking improve the health of all smokers
equally? More speciﬁcally, it addresses the question of whether similar
beneﬁts are obtained with high- and low-risk variants for the well-
established CHRNA5 variant 16969968. They ﬁnd that although the
high-risk variant has a rather large impact on lung cancer risk, develop-
ing cancer 4 years earlier than those with the low-risk variant, the same
beneﬁts can be obtained by quitting smoking independent of genotype.
Indeed, quitting can reduce the risk of developing lung cancer by 50%
and delay its onset by 7 years.
This is an important ﬁnding, but the deeper impact of this paper
involves the question of the nature of the causality of the high-risk
CHRNA5 variant that is linked to the risk of developing lung cancer,
nicotine dependence, and heavy smoking (Bierut et al., 2007; Bierut
et al., 2008; Amos et al., 2008). In efforts to combat smoking and reduce
the incidence of smoking related diseases it is important to understand
the nature of genetic contributions to disease risk. This will help guide
medical advice, patient decisions, and even public policy. One indication
of the nature of this genetic risk allele is that the high-risk allele is
related to other smoking-related diseases in addition to cancer
(Thorgeirsson et al., 2008). This combination of associations would
seem to suggest that the effects of the gene are primarily mediated
through effects on behavior, contributing to heavier smoking, a greater
degree of dependence, and, consequently, a reduced ability to quit
smoking (Baker et al., 2009). If this is indeed the case, then one would
predict that quitting would have equal beneﬁts in individuals with
either the high-risk or low-risk allele, providing they can manage tom.2016.08.012.
. This is an open access article underquit. On the other hand, CHRNA5 variants might have an inﬂuence on
ous studies the beneﬁts of quitting smoking, even for individuals with a
long history of smoking, were quite large, much larger than the risk as-
sociated with CHRNA5 variant alone. Of course, this study addressed
variation in only one risk locus, which by itself is likely to contribute
only a small percentage of the overall risk, as appears to be the case
for addiction genetics generally (Hall, 2016). Nonetheless, it tells a rath-
er important tale about the relationship between lung cancer risk and
the underlying genotype-phenotype relationships that are important
for understanding health outcomes associated with genetic risk in
smoking.
It will be important in future studies to address the nature of the
greater, collective genetic contribution to lung cancer risk. Is the major-
ity of this risk due to genetic inﬂuences on smoking behavior and psy-
chological processes as opposed to a more fundamental biological
predisposition to the development or progression of lung cancer? This
question has important implications for the overlapping ﬁelds of lung
cancer research/treatment and nicotine dependence research/treat-
ment. If the majority of the genes involved in the predisposition to
lung cancer are behavioral, then lung cancer treatment and prevention
approaches need to take this into account. In the broadest sense this
has public policy implications for governmental spending on research
and treatment efforts in this area. A few years ago therewas a suggested
merger of the National Institute on Drug Abuse and the National Insti-
tute on Alcohol Abuse and Alcoholism. There were certainly reasons
for and against the potential merger (Grabowski, 2010; Meyer, 2010),
that eventually weighed into the decision not to merge the institutes.
One of the issues that came out in the debate, however, surrounded
the large research portfolio dedicated to lung cancer research within
theNational Cancer Institute, andwhether future directions in lung can-
cer research/treatment efforts (and funding) might be more proﬁtably
directed a bit more towards the research and treatment of nicotine de-
pendence. The present ﬁndings would seem to suggest that addictive
behavior really lies behind genetic contributions to lung cancer, at
least for this “lung cancer” locus, although certainly more remains to
be done to assess the nature of the wider genetic contributions to lung
cancer risk.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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